World MS Day: National Policy Dialogue Adopts Landmark 10-Point Declaration Calling for Stronger Recognition of Invisible Disabilities in India

2 weeks ago

~Stakeholders urge reforms across disability certification, healthcare access, insurance, workplace inclusion and national health systems to improve outcomes for people…

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight to Decode MET-Driven Biology and Resistance in Advanced NSCLC

2 weeks ago

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma…

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

2 weeks ago

IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising…

Nokia Corporation – Managers’ transactions (Hanrahan)

2 weeks ago

May 31, 2026 06:00 ET  | Source: Nokia Oyj Nokia CorporationManagers’ transactions31 May 2026 at 13:00 EESTNokia Corporation - Managers'…

Crypto News Today: AlphaPepe Hits $1.38M Raised While Bitcoin Price Prediction Targets $250K

2 weeks ago

MONACO, May 30, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after the project announced that its…

Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About

2 weeks ago

New York City, NY, May 30, 2026 (GLOBE NEWSWIRE) -- The global men’s wellness industry continues to grow rapidly, driven…

THE KILLERS ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI

2 weeks ago

Millions of fans from across the world tuned in to watch the iconic rock band's unmissable performance ahead of the…

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

2 weeks ago

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotideData build upon…

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

2 weeks ago

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants…